Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Acquired by Harvey Capital Management Inc.

Harvey Capital Management Inc. boosted its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 86.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 499,570 shares of the company's stock after purchasing an additional 232,180 shares during the period. Harvey Capital Management Inc. owned approximately 0.51% of Aquestive Therapeutics worth $1,449,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Aquestive Therapeutics by 1.9% during the fourth quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company's stock worth $15,474,000 after purchasing an additional 82,958 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in shares of Aquestive Therapeutics by 7.6% during the first quarter. Janney Montgomery Scott LLC now owns 1,059,760 shares of the company's stock valued at $3,073,000 after acquiring an additional 75,275 shares during the period. Bank of America Corp DE increased its stake in shares of Aquestive Therapeutics by 905.2% during the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock valued at $2,457,000 after acquiring an additional 621,614 shares during the period. Northern Trust Corp increased its stake in shares of Aquestive Therapeutics by 3.1% during the fourth quarter. Northern Trust Corp now owns 599,812 shares of the company's stock valued at $2,135,000 after acquiring an additional 18,199 shares during the period. Finally, Bracebridge Capital LLC grew its position in Aquestive Therapeutics by 7.2% in the fourth quarter. Bracebridge Capital LLC now owns 459,216 shares of the company's stock worth $1,635,000 after buying an additional 30,645 shares during the last quarter. Institutional investors own 32.45% of the company's stock.

Wall Street Analyst Weigh In

AQST has been the topic of several research reports. Oppenheimer initiated coverage on Aquestive Therapeutics in a report on Monday, June 2nd. They issued an "outperform" rating and a $7.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, June 17th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $10.14.

Aquestive Therapeutics Stock Performance

Shares of AQST opened at $3.68 on Wednesday. Aquestive Therapeutics, Inc. has a 52 week low of $2.12 and a 52 week high of $5.80. The firm has a market capitalization of $365.53 million, a price-to-earnings ratio of -6.24 and a beta of 1.97. The business's fifty day moving average price is $3.04 and its two-hundred day moving average price is $3.00.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The business had revenue of $8.72 million for the quarter, compared to analysts' expectations of $12.23 million. As a group, research analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Want to see what other hedge funds are holding AQST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.